SCHEMBL569209

SCHEMBL569209

COCCn1c(S(C)(=O)=O)nc2cccnc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.50
TP53 P04637 1/20 0.49
MAPT P10636 1/20 0.48
ALDH1A1 P00352 5/20 0.46
POLB P06746 2/20 0.45
TDP1 Q9NUW8 2/20 0.45
ALOX15 P16050 1/20 0.44
PKM P14618 1/20 0.43
CYP1A2 P05177 3/20 0.43
CYP2C19 P33261 2/20 0.43
GAA P10253 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
HSD17B10 Q99714 3/20 0.40
HPGD P15428 2/20 0.40
OPRM1 P35372 1/20 0.40
OPRD1 P41143 1/20 0.40
OPRK1 P41145 1/20 0.40
LMNA P02545 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1699236 0.83 S1PR1 (0.48) MAPTALDH1A1POLBCYP1A2CYP2C19
SCHEMBL569436 0.78 CYP1A2 (0.43) TP53MAPTPOLBCYP1A2CYP2C19
SCHEMBL569392 0.78 MAPT (0.43) MAPTALDH1A1POLBPKMCYP1A2
SCHEMBL569213 0.77 NPSR1 (0.59) NPSR1TP53MAPTALDH1A1POLB
SCHEMBL19771403 0.76 POLB (0.53) TP53MAPTPOLBTDP1CYP1A2
SCHEMBL928943 0.74 CYP1A2 (0.71) ALDH1A1ALOX15CYP1A2CYP2C19MEN1
SCHEMBL569045 0.72 ALDH1A1 (0.46) NPSR1TP53MAPTALDH1A1POLB
SCHEMBL928089 0.72 CYP1A2 (0.71) ALDH1A1ALOX15CYP1A2CYP2C19MEN1
SCHEMBL17966923 0.72 ENPP2 (0.61) TP53MAPTPOLBCYP1A2CYP2C19
SCHEMBL928085 0.72 CYP1A2 (0.71) TP53ALDH1A1ALOX15CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2601192-B1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICALS CO (JP) 2017-03-01 EP disclosed
EP-2687529-B1 CONDENSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL (JP) 2016-07-13 EP disclosed
US-9029536-B2 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-12 US disclosed
US-9029388-B2 Condensed heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-12 US disclosed
EP-2687529-A1 CONDENSED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2014-01-22 EP disclosed
US-20130331409-A1 CONDENSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-12-12 US disclosed
US-20130172292-A1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-04 US disclosed
EP-2601192-A1 FUSED HETEROCYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2013-06-12 EP disclosed
WO-2012018909-A1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172292-A1 FUSED HETEROCYCLIC COMPOUNDS PDE10A, PDE3A, PDE2A NPSR1 1090/4885TP53 4189/4885MAPT 4109/4885
US-20130331409-A1 CONDENSED HETEROCYCLIC COMPOUND PDE10A, PDE5A, PDE3B NPSR1 1734/4885TP53 3727/4885MAPT 3897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.